StreetInsider.com News Articles

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 04 Sep 2026 09:09:00 -0400

Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City. Dr. Phillip Chan, CEO and Peter Mariani, CFO will be attending the conference, delivering an investor presentation and participating in scheduled 1-on-1 meetings with investors.

Investor Presentation:
Date: Thursday, September 10, 2026
Time: 2:50pm EST
Location: The Westin New York

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 04 Sep 2026 09:09:00 -0400

Investor Presentation:
Date: Thursday, September 10, 2026
Time: 2:50pm EST
Location: The Westin New York

CytoSorbents reports real-world data on bleeding reduction in cardiac surgery

Wed, 02 Sep 2026 07:39:26 -0400

CytoSorbents Corporation (NASDAQ: CTSO) announced results from an independent patient-level matched analysis of real-world data showing that intraoperative use of its CytoSorb device was associated with a 37% relative reduction in severe bleeding among patients undergoing urgent coronary artery bypass grafting (CABG) surgery while on ticagrelor, a blood-thinning medication.

The findings were presented at the European Society of Cardiology Congress on August 29, 2026. The analysis included 587 patients undergoing urgent CABG surgery after recent ticagrelor exposure. Patients treated with CytoSorb (198) from the STAR-T Registry were compared with matched patients (389) who underwent surgery without the device.

The analysis showed a

CytoSorbents reports real-world data on bleeding reduction in cardiac surgery

Wed, 02 Sep 2026 07:39:26 -0400

The analysis showed a

Form 8-K Cytosorbents Corp For: Aug 13

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930343.html

Form 8-K Cytosorbents Corp For: Aug 13

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930343.html

Form 8-K Cytosorbents Corp For: Aug 06

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891032.html

Form 8-K Cytosorbents Corp For: Aug 06

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891032.html

Cytosorbents (CTSO) Misses Q2 EPS by 1c

Thu, 06 Aug 2026 18:12:01 -0400

Cytosorbents (NASDAQ: CTSO) reported Q2 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $9.63 million versus the consensus estimate of $9.42 million.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update